TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31533823
Drug: Yoga therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga therapy (60 min sessions for 8 weeks)
Study: 26863442
Drug: SHAM (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHAM (0.1 g·kg(‐1) NaCl, 4 mL·kg(‐1) carbonated water, and 1 mL·kg(‐1) squash)
Study: 26863442
Drug: PLA (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLA (0.1 g·kg(‐1) sodium chloride (NaCl), 4 mL·kg(‐1) tap water, and 1 mL·kg(‐1) squash)
Study: 24736440
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of zidovudine
Study: 22648714
Drug: Soy isoflavone
Normalized name: soy isoflavone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavone intake of ≥10 mg/d
Study: 17891596
Drug: Dydrogesterone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dydrogesterone (10 mg/day on days 1-14)
Study: 9526519
Drug: Supranormal oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supranormal oxygen delivery and consumption therapy (volume expansion and dobutamine 3 to 15 micrograms/kg/min for 12 hours)
Study: 9526519
Drug: Normal hemodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal hemodynamic values therapy (control group)
Study: 2498513
Drug: Gold sodium
Normalized name: Gold Sodium Thiomalate
DrugBank: Gold (DB14154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold sodium thiomalate (GSTM) 50 mg IM weekly + placebo
Study: 2498513
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 12.5 mg weekly (oral and noncycled) + placebo
Study: 2498513
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (GSTM and MTX)
Study: 31168085
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (specific dosage and duration not mentioned)
Study: 19472437
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination containing acetylsalicylic acid, paracetamol, and caffeine (randomized phase)
Study: 19472437
Drug: Single agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agents acetylsalicylic acid and paracetamol (randomized phase)
Study: 19472437
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination containing acetylsalicylic acid, paracetamol, and caffeine (open-label phase)
Study: 19472437
Drug: Single agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agents acetylsalicylic acid, paracetamol, and ibuprofen (open-label phase)
Study: 19472437
Drug: Single agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agents acetylsalicylic acid and paracetamol (open-label phase)
Study: 17301210
Drug: Medication Discharge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Discharge Worksheet (MDW)
Study: 11059636
Drug: Candesartan cilexetil,
Normalized name: Candesartan Cilexetil, 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan cilexetil, 8 or 16 mg once daily
Study: 8444272
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (750 mg daily for 2-3 weeks)
Study: 3523551
Drug: Helium-neon (He-Ne)
Normalized name: neon
DrugBank: Neon (DB11589)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helium-neon (He-Ne) laser treatment
Study: 27015689
Drug: Motor and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motor and cognitive rehabilitation (20-week programme consisting of active self-correction, task-oriented exercises, and cognitive-behavioural therapy)
Study: 22419263
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic Acid (TA) group (n = 25, 500 mg/5 ml tranexamic acid)
Study: 22419263
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 25, 5 ml 0.9% saline)
Study: 20013115
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg regular release (RR)
Study: 20013115
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg sustained release (SR)
Study: 20013115
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg surge-sustained release (SSR)
Study: 18684855
Drug: Acyclovir 400
Normalized name: acyclovir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 400 mg twice a day for 12 weeks
Study: 17117564
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment for 3-4 weeks, 5 times each week, plus routine therapy
Study: 7549379
Drug: Routine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine therapy alone
Study: 14685287
Drug: Bolus group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus group (10 units of oxytocin administered over 30 seconds)
Study: 14685287
Drug: Drip group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drip group (10 units of oxytocin administered over 5 minutes)
Study: 14685287
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no oxytocin administration)
Study: 25552412
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 10 mL 10% calcium gluconate in 100 mL 0.9% saline solution
Study: 25552412
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group received 100 mL 0.9% saline solution
Study: 23330988
Drug: Implant-supported fixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-supported fixed prostheses (Group A)
Study: 19103360
Drug: Medium-dose ultraviolet
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose ultraviolet A1 (MD UVA1)
Study: 11910567
Drug: TAC plus
Normalized name: ACETAMINOPHEN 325 mg / PHENYLEPHRINE HYDROCHLORIDE 5 mg / DEXTROMETHORPHAN HYDROBROMIDE 15 mg / GUAIFENESIN 200 mg ORAL TABLET [COLDTAC Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC plus GEL
Study: 10707135
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg anthocyanosides
Study: 10707135
Drug: 24 mg
Normalized name: uracil 224 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mg anthocyanosides
Study: 10325997
Drug: 36 mg
Normalized name: pyrantel 136 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36 mg anthocyanosides
Study: 2707638
Drug: Elemental calcium
Normalized name: Elemental calcium
DrugBank: Calcium (DB01373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elemental calcium 1200 mg/day
Study: 330307
Drug: Bismuth subsalicylate
Normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth subsalicylate (30 ml each 1/2 hr until eight doses, total dose of 4.2 g)
Study: 330307
Drug: Bismuth subsalicylate
Normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth subsalicylate (higher dose of 8.2 g over 3 1/2‐hr treatment period)
Study: 7054318
Drug: CR virus
Normalized name: hepatitis A virus strain CR 326F antigen, inactivated Injection [Vaqta]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR virus vaccine
Study: 24423299
Drug: Heparin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin administration in nonpregnant women (n = 8, 15, 16)
Study: 24423299
Drug: Heparin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin administration in nonpregnant women
Study: 26581547
Drug: Dacomitinib 45
Normalized name: dacomitinib 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacomitinib 45 mg once daily
Study: 22753918
Drug: Dacomitinib 45
Normalized name: dacomitinib 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacomitinib 45 mg once daily in KRAS wild-type tumors
Study: 22753918
Drug: Dacomitinib 45
Normalized name: dacomitinib 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacomitinib 45 mg once daily in KRAS wild-type/EGFR wild-type tumors
Study: 24827134
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg once daily
Study: 22753918
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg once daily in KRAS wild-type tumors
Study: 22753918
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg once daily in KRAS wild-type/EGFR wild-type tumors
Study: 20185783
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg tenecteplase
Study: 20185783
Drug: 0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg tenecteplase
Study: 20185783
Drug: 0.9 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mg/kg rtPA
Study: 11064762
Drug: Ivermectin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (200 micrograms/kg) + DEC (6 mg/kg)
Study: 11064762
Drug: Ivermectin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (200 micrograms/kg) + Albendazole (400 mg)
Study: 11064762
Drug: DEC (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEC (6 mg/kg) + Albendazole (400 mg)
Study: 11064762
Drug: DEC (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEC (6 mg/kg) + Ivermectin (200 micrograms/kg)
Study: 9232072
Drug: Cardioplegia with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardioplegia with intermittent cristalloid using SLF11 solution
Study: 8399865
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V (2 g)
Study: 8399865
Drug: Amoxicillin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (3 g)
Study: 2439783
Drug: Bisoprolol 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 20 mg/d
Study: 2439783
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg/d
Study: 2439783
Drug: Atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 100 mg/d
Study: 21401534
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behaviour therapy (CBT) for 10 weeks
Study: 19629797
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behaviour therapy (CBT)
Study: 25425539
Drug: Erythromycin 250
Normalized name: erythromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 250 mg once a day for 3 months
Study: 23527823
Drug: Inhaled dry
Normalized name: Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled dry powder apomorphine (VR040)
Study: 22036610
Drug: Single treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single treatment pass with Q‐switched alexandrite laser (5.5 J/cm(2), 755 nm, 100‐nanosecond pulse duration, 3‐mm spot size)
Study: 22036610
Drug: 4 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 treatment passes with Q‐switched alexandrite laser, 20 minutes apart (R20 method)
Study: 17430659
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy followed by adjuvant chemotherapy (weekly cisplatin 25 mg/m2 for 6 weeks, radiotherapy at 2 Gy/day to a total of 70 Gy, followed by cisplatin 25 mg/m2 and 5‐fluorouracil 1000 mg/m2 for 3 days every 3 weeks for 3 cycles)
Study: 17430659
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy followed by adjuvant chemotherapy
Study: 7888536
Drug: Didanosine (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine (specific dosage and duration not mentioned)
Study: 3540668
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium (2000 mg daily)
Study: 31195326
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) 1000–3000 mg/day
Study: 31195326
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) 200–400 mg/day
Study: 28447206
Drug: Urate-lowering therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urate-lowering therapy (ULT) for 6 months
Study: 24240384
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (LA) treatment
Study: 21888656
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no praziquantel treatment)
Study: 17854525
Drug: High-dose GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose GnRH antagonist (2 mg/day) + recombinant LH (375 IU/day)
Study: 17854525
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0.25 mg/day GnRH antagonist)
Study: 17854525
Drug: High-dose GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose GnRH antagonist + recombinant LH
Study: 15502029
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of IV fentanyl formulation (approximately 10‐15 microg/kg; maximum, 400 microg)
Study: 9840314
Drug: Ketoacid-aminoacid-supplemented very
Normalized name: Primula veris extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoacid-aminoacid-supplemented very low protein diet (diet K, 0.28 g/kg/d)
Study: 9840314
Drug: Amino acid-supplemented
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid-supplemented very low protein diet (diet J, 0.28 g/kg/d)
Study: 9840314
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein diet (diet L, 0.575 g/kg/d)
Study: 9840314
Drug: Usual protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual protein diet (diet M, 1.2 g/kg/d)
Study: 30997631
Drug: PEDEM supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEDEM supplementation at 12 mg
Study: 30997631
Drug: PEDEM supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEDEM supplementation at 14 mg
Study: 30997631
Drug: PEDEM supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEDEM supplementation (various doses)
Study: 26573069
Drug: Imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400 mg daily for 2 years
Study: 26573069
Drug: Observation (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation (no further therapy)
Study: 26573069
Drug: Imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400 mg daily for 2 years (high-risk subgroup)
Study: 26573069
Drug: Observation (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation (no further therapy) (high-risk subgroup)
Study: 26573069
Drug: Imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400 mg daily for 2 years (centrally reviewed high-risk subgroup)
Study: 26573069
Drug: Observation (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation (no further therapy) (centrally reviewed high-risk subgroup)
Study: 23075258
Drug: Postcard intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postcard intervention (monthly for five months plus usual care)
Study: 1927938
Drug: Sustained-release isosorbide
Normalized name: isosorbide Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release isosorbide dinitrate 120 mg
Study: 1927938
Drug: Sustained-release diltiazem
Normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release diltiazem 120 mg
Study: 1927938
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of isosorbide dinitrate and diltiazem
Study: 30661513
Drug: Tolterodine extended
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine extended release 4 mg (TER4)
Study: 28329397
Drug: Resveratrol (2-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (2-3 g/daily)
Study: 29809375
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg per oral once daily for three months
Study: 29809375
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg per oral once daily for three months
Study: 22549879
Drug: rilonacept 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: rilonacept 80 mg
Study: 22549879
Drug: rilonacept 160
Normalized name: RILONACEPT 160 mg in 2 mL SUBCUTANEOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [Arcalyst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: rilonacept 160 mg
Study: 21206331
Drug: Intravenous nafamostat
Normalized name: Nafamostat
DrugBank: Nafamostat (DB12598)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Intravenous nafamostat mesilate
Study: 7915235
Drug: Suriclone (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suriclone (0.4 mg) + Chlorpromazine (50 mg)
Study: 7915235
Drug: Zopiclone (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone (7.5 mg) + Chlorpromazine (50 mg)
Study: 7915235
Drug: Suriclone (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suriclone (0.4 mg)
Study: 28594757
Drug: Lidocaine‐prilocaine cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine‐prilocaine cream
Study: 18499602
Drug: Passiflora incarnata
Normalized name: Passiflora incarnata
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passiflora incarnata (500 mg, Passipy IranDarouk)
Study: 16595611
Drug: Dexmedetomidine 1
Normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 microg kg(‐1) over 10 min; followed by 0.1‐0.7 microg kg(‐1) h(‐1) i.v. infusion (Group D)
Study: 16595611
Drug: Midazolam 20
Normalized name: midazolam 200 mg/200 mL-D5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 20 microg kg(‐1) i.v.; followed by 0.5 mg i.v. boluses as required (Group M)
Study: 12700794
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (250 micro;g) + Iron (120 mg)
Study: 12700794
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (250 micro;g) + Iron (80 mg)
Study: 12700794
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (250 micro;g) + Zinc sulfate + Iron (120 mg)
Study: 12700794
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (250 micro;g) + Zinc sulfate + Iron (80 mg)
Study: 12700794
Drug: Iron (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron (120 mg) only (routine dosage)
Study: 10993035
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol patch (Climara) applied on buttocks
Study: 10993035
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol patch (Climara) applied on abdomen
Study: 9140141
Drug: Oral vanadyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vanadyl sulphate (0.5 mg/kg/day)
Study: 3470356
Drug: Periodontal ligament
Normalized name: human ligament preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal ligament injection using pistol-pressure syringe
Study: 3470356
Drug: Periodontal ligament
Normalized name: human ligament preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal ligament injection using standard-grip syringe
Study: 3470356
Drug: Type of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type of syringe and solution injected
Study: 27034455
Drug: Automated interactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated interactive voice response tool providing real-time patient-reported data, with three brief interactive calls every 2 months after medication prescription.
Study: 25154739
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (SeR-Se-Ly + tamsulosin 0.4 mg)
Study: 18853232
Drug: Wholemeal wheat
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wholemeal wheat bread (WB) (133 g)
Study: 18853232
Drug: Glucose (55
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (55 g) in water
Study: 17145606
Drug: Hydroxyurea capsules
Normalized name: Hydroxyurea Capsules
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea capsules
Study: 17145606
Drug: Hydroxyurea tablets
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea tablets
Study: 14524645
Drug: Intermittent SSRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent SSRI therapy
Study: 1542320
Drug: Fluconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (400 mg daily)
Study: 8922787
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (25-50 mg daily; 0.67 mg/kg daily for neutropenic patients)
Study: 1551115
Drug: Thioether-lipid conjugate
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thioether-lipid conjugate of ara-C (ara-CDP-DL-PTBA) at 250 mg/kg/week for 3 weeks